Phaseline

Companies › Anagram Therapeutics

Anagram Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ANG003 Dose A
Pancreatic enzyme replacement therapy (lipase, protease, amylase)
–Phase 2Exocrine Pancreatic Insufficiency (EPI)Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07450547ANG003 Dose APhase 2Exocrine Pancreatic Insufficiency (EPI)RespiratoryJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense ReCode Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.